| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/14/2006 | CA2450740C Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/14/2006 | CA2375385C Propargyl phenyl ether a2a receptor agonists |
| 02/14/2006 | CA2374643C 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists |
| 02/14/2006 | CA2363145C Oxamic acids and derivatives as thyroid receptor ligands |
| 02/14/2006 | CA2338684C Injectable propofol formulations |
| 02/14/2006 | CA2336597C Hepatitis c inhibitor peptides |
| 02/14/2006 | CA2269072C Vascular endothelial growth factor (vegf) nucleic acid ligand complexes |
| 02/14/2006 | CA2210044C 4-hydroxy-piperidine derivatives |
| 02/14/2006 | CA2192645C Tri-substituted phenyl derivatives useful as pde iv inhibitors |
| 02/14/2006 | CA2190148C Oral liquid alendronate formulations |
| 02/14/2006 | CA2105666C New centrally acting substituted phenylazacycloalkanes |
| 02/09/2006 | WO2006014024A1 Therapeutic agent for psychoneurotic disease |
| 02/09/2006 | WO2006013948A1 Triazole derivative |
| 02/09/2006 | WO2006013929A1 Composition for accelerating calcium absorption |
| 02/09/2006 | WO2006013914A1 Preparation for administration to mouth mucosa |
| 02/09/2006 | WO2006013904A1 Medicinal composition containing meltrin antagonist |
| 02/09/2006 | WO2006013873A1 Drugs having cyclooxygenase inhibiting activity |
| 02/09/2006 | WO2003090691A3 Method and compositions for identifying anti-hiv therapeutic compounds |
| 02/09/2006 | WO2002088316A3 G-protein coupled receptors |
| 02/09/2006 | US20060031946 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
| 02/09/2006 | US20060030720 Method for synthesizing macrosphelides |
| 02/09/2006 | US20060030713 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation |
| 02/09/2006 | US20060030622 Compounds and methods for the treatment of urogenital disorders |
| 02/09/2006 | US20060030618 Vanilloid receptor ligands and their use in treatments |
| 02/09/2006 | US20060030614 dissolving in a solvent, precipitating crystal form by cooling the solution to about -20C |
| 02/09/2006 | US20060030605 Pharmaceutical compounds |
| 02/09/2006 | US20060030604 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| 02/09/2006 | US20060030598 Thiazolyl inhibitors of Tec family tyrosine kinases |
| 02/09/2006 | US20060030593 1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/09/2006 | US20060030592 I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| 02/09/2006 | US20060030580 Contacting phenolic piperidines with opioid receptors; analgesics, anticonvulsants, antitussive agents; diarrhea, drug addiction |
| 02/09/2006 | US20060030576 Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| 02/09/2006 | US20060030573 melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes |
| 02/09/2006 | US20060030568 Crystal modificaion of a N-phenyl-2-pyrimidineamine derivative, processed for its manufacture and its use |
| 02/09/2006 | US20060030561 2-Benzyl-2-hydroxy-4-methyl-4-phenylpentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide for example; treating type II diabetes, obesity, hypertension, arteriosclerosis, or glaucoma |
| 02/09/2006 | US20060030540 Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent |
| 02/09/2006 | US20060030005 C3b/C4b complement receptor-like molecules and uses thereof |
| 02/09/2006 | US20060029605 Use of ErbB receptor ligands in treating diabetes |
| 02/09/2006 | US20060029602 secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner |
| 02/09/2006 | US20060029599 Lyophilizing an aqueous formulation comprising a high concentration, 50 mg/ml or more of an immunoglobulin IgG antibody, in particular, daclizumab, in 5-25 mM histidine buffer, having pH 5.5-6.5, 0.005%-0.03% polysorbate, and sucrose |
| 02/09/2006 | US20060029598 Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions |
| 02/09/2006 | US20060029596 Administering to the tumor an adenovirus vector, overexpresses an adenovirus death protein; promoting the death of neoplastic cells; telomerase resistance; anticancer biodrugs |
| 02/09/2006 | US20060029595 Methods of using human receptor protein 4-1BB |
| 02/09/2006 | US20060029584 Methods for improving cell line activity in immunoisolation devices |
| 02/09/2006 | DE69717294C5 Chinazolin derivate und diese enthaltende pharmazeutische zusammenstellungen Quinazoline derivatives and those containing pharmaceutical assortments |
| 02/09/2006 | CA2580235A1 Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors |
| 02/09/2006 | CA2576093A1 Pharmaceutical compostion containing meltrin antagonist |
| 02/09/2006 | CA2576022A1 Composition for accelerating calcium absorption |
| 02/09/2006 | CA2573198A1 Nicotinamide derivatives and their use as therapeutic agents |
| 02/08/2006 | EP1623994A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 02/08/2006 | EP1623984A1 Polymorphic form I of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt |
| 02/08/2006 | EP1623974A1 2"-hydroxynicotianamine, process for producing the same and angiotensin converting enzyme inhibitor, hypotensive drug and health food |
| 02/08/2006 | EP1623718A1 Skin collagen production promoter |
| 02/08/2006 | EP1623710A1 Receptor antagonist |
| 02/08/2006 | EP1623708A2 Pharmaceutical composition comprising acetyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism |
| 02/08/2006 | EP1623707A1 Medicinal composition for treating sudden deafness |
| 02/08/2006 | EP1623704A1 Therapeutic agent |
| 02/08/2006 | EP1622609A2 Methods for treating degenerative diseases/injuries |
| 02/08/2006 | EP1423168B1 Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use |
| 02/08/2006 | EP1358162B1 Dihydroindole and tetrahydroquinoline derivatives |
| 02/08/2006 | EP1265871B1 Pyridazinyl phenyl hydrazones useful against congestive heart failure |
| 02/08/2006 | EP1235776B1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 02/08/2006 | EP1187815B1 4-phenyl-pyrimidine derivatives |
| 02/08/2006 | EP1144348B1 Lta 4 hydrolase inhibitors |
| 02/08/2006 | EP1112362B1 GENE MODIFICATION IN THE GENE FOR THE DIE G$g(b)3-SUB-UNIT OF HUMAN G-PROTEIN |
| 02/08/2006 | EP0971587B1 Quinoline leukotriene antagonists |
| 02/08/2006 | EP0812356B1 Prostate-specific membrane antigen and uses thereof |
| 02/08/2006 | CN1732161A 1,3-diamino-2-hydroxypropane pro-drug derivatives |
| 02/08/2006 | CN1731989A A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 02/08/2006 | CN1730087A Wind dispelling drop pill containing amomum fruit and process for preparing the same |
| 02/08/2006 | CN1730063A Chondriosome protective pill and its prescription |
| 02/08/2006 | CN1730061A Medicine for lowering serum glutamic pyruvic transaminase |
| 02/08/2006 | CN1729991A Dripping pills of tripterigium wilfordi glycosides and its preparation process |
| 02/08/2006 | CN1729984A Freeze dry formulation of fasudil hydrochloride and its preparation process |
| 02/08/2006 | CN1240842C Oligonucleotide - facilitated coalescence |
| 02/08/2006 | CN1240836C Transforming growth factor alpha HI |
| 02/08/2006 | CN1240713C New compound |
| 02/08/2006 | CN1240711C Novel peptide having angiotensin convertase inhibitory effect |
| 02/08/2006 | CN1240688C Quinazoline compounds |
| 02/08/2006 | CN1240684C Dibenzocycloheptene compound |
| 02/08/2006 | CN1240437C Oral administered self-emulsifying formulations of pyranone proteinase inhibitors |
| 02/08/2006 | CN1240430C Medicine for preventing and treating chronic exhaustion syndrome |
| 02/08/2006 | CN1240403C Echinacea composition and method of manufacture |
| 02/08/2006 | CN1240392C Agent for promoting cell activation for external use |
| 02/08/2006 | CN1240390C Biologic converted ginseng composition and preparing process thereof |
| 02/08/2006 | CN1240387C Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 02/08/2006 | CN1240386C Matrix metal proteinase and tumor necrosis inhibitor |
| 02/08/2006 | CN1240382C Medicine combinations using pyridoindolone derivatives and anticancer agent as base |
| 02/08/2006 | CN1240379C Lipid peroxide-lowering compositions |
| 02/08/2006 | CN1240377C Stable pharmaceutical composition of pravastatin |
| 02/08/2006 | CN1240372C Incorporation of exogenous lactic acid bacteria into oral microflora |
| 02/08/2006 | CN1240317C Method for preparing beverage with natural food ferment and product thereof |
| 02/07/2006 | US6995269 Guanidinobenzamides |
| 02/07/2006 | US6995261 Treatment of meningitis, septic shock, infections, reperfusion injuries, hepatitis, pancreatitis; bone, autoimmune, viral, and respiratory system disorders; antiinflammatory, antiarthritic, and antitumor agents |
| 02/07/2006 | US6995189 comprises fatty acids; for treatment/prevention of sepsis or inflammatory shock |
| 02/07/2006 | US6995184 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/07/2006 | US6995182 1-sulfonyl pyrrolidine derivatives |
| 02/07/2006 | US6995177 HCV NS3 protease inhibitors |
| 02/07/2006 | US6995176 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/07/2006 | US6995175 Anticancer agents |